How new drugs, tech, and habits are reshaping cardiovascular prevention

This cluster tracks a shift in cardiovascular and metabolic care toward earlier prevention, smarter risk prediction, and more aggressive treatment of obesity and dyslipidemia. It spans cost-effectiveness of GLP‑1–based therapies, evolving statin and lipid guidance, emerging treatments for cardiac amyloidosis, and concerns that current risk calculators may miss younger adults and women as heart disease rises in these groups. At the same time, AI-enabled tools, robotic interventions, and smartwatch ECG analytics are expanding how we detect and manage disease, while research on exercise “snacks,” mobility, sleep, and community-based physical activity reinforces lifestyle medicine as a powerful, system-level strategy that may even reduce clinician burnout. Together these developments highlight a future where medications, technology, and everyday behaviors are tightly integrated to curb the leading causes of death.